Emmaus Life Sciences Reports 38% Revenue Decline and Increased Net Loss in Q3 2025

Emmaus Life Sciences, Inc. reported a significant decline in financial performance for the third quarter of 2025, with net revenues falling to $3.4 million, a decrease of 38% from $5.5 million in the same period last year. For the nine months ending September 30, 2025, total revenues were $8.6 million, down 36% from $13.4 million in 2024. The company attributed this decline primarily to increased competition from a generic version of its only product, Endari® (L-glutamine oral powder), which was launched by ANI Pharmaceuticals in mid-2024, as well as reduced sales in the Middle East and North Africa (MENA) region.

The company's cost of goods sold also decreased, reflecting the drop in sales, totaling $0.2 million for the quarter and $0.6 million for the nine-month period. Operating expenses saw a notable reduction, with research and development costs down to $50,000 for the quarter, a 66% decrease, and selling expenses reduced by 50% to $0.7 million. General and administrative expenses also fell by 38% to $1.7 million, largely due to lower payroll and professional service costs. Despite these reductions, Emmaus reported a net loss of $2.1 million for the quarter, compared to a net income of $1.8 million in the prior year, and a net loss of $5.5 million for the nine months, up from a loss of $4.7 million in 2024.

As of September 30, 2025, Emmaus had total assets of $20.8 million, down from $23.6 million at the end of 2024. The company’s cash and cash equivalents were significantly reduced to $0.3 million, compared to $1.4 million at the end of the previous year. Current liabilities increased slightly to $80.2 million, with accounts payable and accrued expenses rising to $21.8 million. The accumulated deficit grew to $268.1 million, indicating ongoing financial challenges.

Strategically, Emmaus continues to focus on the commercialization of Endari® in the MENA region, where it has received approvals in several countries, including the UAE, Qatar, Kuwait, and Oman. However, the company faces substantial uncertainty regarding its ability to meet its current liabilities and operational expenses, raising doubts about its ability to continue as a going concern. Management indicated that future cash requirements would likely need to be met through additional financing, including loans and potential equity offerings.

Looking ahead, Emmaus has expressed concerns about its ability to generate sufficient revenues to sustain operations without raising additional capital. The company is exploring various financing options, including loans from related parties and potential strategic partnerships. However, there is no assurance that these efforts will be successful, and the company remains cautious about its financial outlook for the coming months.